12 phenothrin, membrane fusion 13 Word Count (Abstract): 221 14 Word Count (Text): 4,034 ABSTRACT Lassa virus (LASV) belongs to the Mammarenavirus genus (family 22 Arenaviridae) and causes severe hemorrhagic fever in humans. At present, there are 23 no Food and Drug Administration (FDA)-approved drugs or vaccines specific for 24 LASV. Herein, high-throughput screening of an FDA-approved drug library was 25 performed against LASV entry using a pseudo-type virus enveloping LASV 26 glycoproteins. Two hit drugs, lacidipine and phenothrin, were identified as LASV 27 entry inhibitors in the micromolar range. A mechanistic study revealed that both drugs 28 inhibited LASV entry by blocking low-pH-induced membrane fusion. Moreover, 29 lacidipine irreversibly bound to the LASV glycoprotein complex (GPC), resulting in 30 virucidal activity. Adaptive mutant analyses demonstrated that replacement of T40, 31 located in the ectodomain of the stable-signal peptide (SSP), with lysine (K) conferred 32
non-covalently associates with GP2; many arenavirus entry inhibitors have been 126 shown to bind with and stabilize the prefusion forms of GPC to prevent membrane 127 fusion (26-28); therefore, we asked whether the 2 hit drugs act via a similar 128 mechanism. To address this, 293T cells transfected with GPC were incubated with 129 either drug and subjected to a low-pH pulse to promote fusion. As shown in Fig. 2A, a   130 low pH in the GPC-transfected cells induced obvious membrane fusion, whereas a 131 7 neutral pH had no effect. Both drugs inhibited syncytium formation at all tested 132 concentrations, suggesting that both drugs inhibit GPC conformational changes 133 induced by an acidic environment. 134 To further quantitatively evaluate the inhibitory activities, fusion efficacy was 135 determined using a dual-luciferase assay. As shown in Fig. 2B , the maximum 136 inhibitory rates for lacidipine and phenothrin were 42.4% and 81.2%, respectively, at 137 the range of concentrations tested. Notably, phenothrin exhibited great activity (~80%) 138 against GPC-mediated membrane fusion even at the lowest concentration tested (12.5 139 μM). Together, these results show that both drugs, especially phenothrin, prominently 140 inhibit GPC-mediated membrane fusion.
141
Lacidipine Irreversibly Binds to GPC. Lacidipine and phenothrin inhibited 142 GPC-mediated membrane fusion; therefore, we asked whether the drugs irreversibly 143 bind to GPC and prevent conformational changes. To test this, we conducted a 144 virucidal assay to investigate the binding ability of the hit drugs to native GPC. 145 LASVpv was mixed with drugs for 1 h; the mixture was then diluted 200-fold and 146 added to the cells for 1 h. As shown in Fig. 3A , luciferase activity was not suppressed 147 in the phenothrin group, indicating that phenothrin did not irreversibly bind to the 148 neutral-pH forms of GPC (29). However, it is possible that phenothrin binds to a 149 structural GPC intermediate resulting from the low pH. A reduction > 70% was 150 observed in the lacidipine group, suggesting that lacidipine irreversibly interacts with 151 the pre-fusion conformation of GPC and inhibits LASV entry. 152 We next investigated the inhibitory effects of the drugs on binding, which is 153 8 initialized when GP1, the receptor binding subunit, recognizes the primary receptor 154 α-DG (18). Binding efficacy was evaluated in the absence and presence of the drugs, 155 and no significant decrease in the number of LASVpv particles bound to the cell 156 surface at 4°C was observed in either drug-treated group (Fig. 3B ), suggesting that 157 neither drug interferes with the receptor binding subunit GP1 (38, 39).
158
To further confirm drug mechanisms, we studied the inhibition kinetics of lacidipine When viruses were treated with 10 μM lacidipine, the viral titer after 12 rounds of 171 passaging was about 100-fold higher than that in the wild type (WT) virus ( Fig. 4A ).
172
The lacidipine-resistant virus isolate was plaque purified and sequenced for the entire 173 glycoprotein precursor GPC region. An amino acid substitution was observed in the 174 isolated clone, but markedly absent in the DMSO-treated virus, resulting in a revealed that the T40K plaques were similar to the WT plaques, whereas T40R and 195 T40D plaques were smaller, and T40A plaques were mid-range. These results 196 suggested that the infectivity of SSP T40R and T40D mutant viruses is milder than 197 10 that of the WT virus, and position 40 in SSP was tolerable for K. 198 We next investigated sensitivity of the four mutant viruses to lacidipine. As shown in were resistant to lacidipine, with the viral titer decreasing slightly less than 1 log unit; 203 the T40A mutant virus showed no resistance to lacidipine.
204
Taken together, these results suggest that the T40 mutant was not only critical in (Fig. 6A) . To investigate the functional significance of these residues, a 240 pseudo-type GTOV containing the mutants was used to evaluate lacidipine sensitivity. 241 12 GTOV was much less sensitive when either the V36M or V436A mutant was 242 generated, and lacidipine sensitivity was further reduced when both sites were 243 changed ( Fig. 6B ). As V36 is similarly conserved in NW pathogenic viruses, we 244 reasoned that residues other than these selective mutations contributed to the 245 sensitivity of LASV and GTOV to lacidipine. acid sequence conservation, and the overall GP1-GP2 structure of LASV aligns well 293 with LCMV (42, 43); however, the interplay between SSP and GP2 involves a 294 multiple sequential correlation and is not limited at the point-to-point sub interface.
295
Lacidipine-sensitivity depends on accessibility of the interface to the drug as well as 296 the stability of the drug-GPC complex. 297 We also identified phenothrin via HTS; phenothrin is a pyrethroid usually used in 298 pesticide products and is effective at inhibiting LASV entry. We demonstrated that 299 phenothrin has activity against MOPV, GTOV, and CHPV, with IC50 values lower 300 than 10 μM. The structure of phenothrin is similar to that of the LASV specific entry 301 inhibitor ST-161, which uses a cyclopropyl N-acylhydrazone as a scaffold (26, 44). In 302 our study, resistant viruses for LASV or GTOV were not successfully generated in the 303 presence of phenothrin, suggesting this drug is less prone to induce adaptive 
